Examination of Tamoxifen in Acute Mania in Patients With Bipolar I Disorder
A Double-Blind Study Examining the Efficacy of the Protein Kinase C Inhibitor Tamoxifen in the Treatment of Acute Mania
Sponsor: National Institute of Mental Health (NIMH)
Listed as NCT00026585, this PHASE2 trial focuses on Bipolar Disorder and remains completed. Sponsored by National Institute of Mental Health (NIMH), it has been updated 7 times since 2001, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Aug 2017 [monthly]
Completed PHASE2
First recorded
Nov 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Mental Health (NIMH)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Washington D.C., United States